Want to see HK:2500 full AI Analyst Report?
2500 Stock Chart & Stats
HK$2.46
HK$0.00(0.00%)
At close: 4:00 PM EDT
HK$2.46
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$1.01 - HK$5.47
Previous CloseN/A
Volume6.42M
Average Volume (3M)2.48M
Market Cap
HK$498.34M
Enterprise ValueHK$970.85
Total Cash (Recent Filing)HK$280.52M
Total Debt (Recent Filing)HK$216.43M
Price to Earnings (P/E)―
Beta0.40
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding441,010,220
10 Day Avg. Volume2,133,843
30 Day Avg. Volume2,483,027
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.53
Price to Sales (P/S)3.05
P/FCF Ratio-2.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)HK$791.75M
Bulls Say, Bears Say
Bulls Say
TAVI / Structural Heart SpecializationA focused product portfolio centered on TAVI and structural heart devices creates a durable niche with high clinical and regulatory barriers to entry. This specialization supports long-term commercial relevance as hospitals adopt transcatheter approaches and vendors with clinical expertise and product suites gain durable preference.
Improving Balance Sheet LeverageMaterial improvement in debt-to-equity to ~0.12 reduces refinancing and solvency risk, providing financial flexibility. A healthier balance sheet supports continued R&D and commercial investment over months and lessens short-term liquidity pressure versus peers with high leverage.
Product-level Gross Margin StrengthSustained solid gross margins indicate that core products retain unit-level profitability. If fixed costs are controlled and revenue stabilizes, margins provide a credible pathway to operating leverage and eventual profitability, making product economics a durable strength.
Bears Say
Sharp Recent Revenue DeclineA roughly 30% revenue drop in 2025 materially reduces scale and undermines operating leverage. Lower procedure volumes or loss of market traction can persist for quarters, limiting the company’s ability to absorb fixed costs and invest in commercialization, slowing any recovery.
Structural UnprofitabilityPersistent operating and net losses indicate the business has not yet converted product economics into shareholder returns. Continued losses will pressure equity, constrain reinvestment capacity, and may force difficult cost or strategy changes unless a durable profitability path emerges.
Weak And Deteriorating Cash FlowRecurrent negative operating and free cash flows, and a sharp 2025 deterioration, raise funding and execution risk. Reliance on external capital could dilute shareholders or limit long-term investments, impairing the company’s ability to scale commercialization and sustain R&D.
Venus Medtech (Hangzhou), Inc. Class H News
2500 FAQ
What was Venus Medtech (Hangzhou), Inc. Class H’s price range in the past 12 months?
Venus Medtech (Hangzhou), Inc. Class H lowest stock price was HK$1.01 and its highest was HK$5.47 in the past 12 months.
What is Venus Medtech (Hangzhou), Inc. Class H’s market cap?
Venus Medtech (Hangzhou), Inc. Class H’s market cap is HK$498.34M.
When is Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date?
Venus Medtech (Hangzhou), Inc. Class H’s upcoming earnings report date is Aug 27, 2026 which is in 22 days.
How were Venus Medtech (Hangzhou), Inc. Class H’s earnings last quarter?
Venus Medtech (Hangzhou), Inc. Class H released its earnings results on Mar 31, 2026. The company reported -HK$0.682 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Venus Medtech (Hangzhou), Inc. Class H overvalued?
According to Wall Street analysts Venus Medtech (Hangzhou), Inc. Class H’s price is currently Overvalued.
Does Venus Medtech (Hangzhou), Inc. Class H pay dividends?
Venus Medtech (Hangzhou), Inc. Class H does not currently pay dividends.
What is Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate?
Venus Medtech (Hangzhou), Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Venus Medtech (Hangzhou), Inc. Class H have?
Venus Medtech (Hangzhou), Inc. Class H has 441,010,220 shares outstanding.
What happened to Venus Medtech (Hangzhou), Inc. Class H’s price movement after its last earnings report?
Venus Medtech (Hangzhou), Inc. Class H reported an EPS of -HK$0.682 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.543%.
Which hedge fund is a major shareholder of Venus Medtech (Hangzhou), Inc. Class H?
Currently, no hedge funds are holding shares in HK:2500
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Venus Medtech (Hangzhou), Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.86%
Trailing 12-Months
Company Description
Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.
Technical Analysis
MicroPort Scientific
―
MicroPort CardioFlow Medtech Corp.
―
MicroTech Medical (Hangzhou) Co., Ltd. Class H
―
Shanghai MicroPort MedBot (Group) Co., Ltd. Class H
―
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
―